European Leukemia Trial Registry
Trial: JAKARTA2

More Details
Title SAR302503 In MF Previously Treated With Ruxolitinib
Scientific Title A Phase II, Multicenter, Open Label, Single Arm Study of SAR302503 in Subjects Previously Treated With Ruxolitinib and With a Current Diagnosis of Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
Short Title JAKARTA2
Trialgroup NN
Type of Trial multicentric, single-group, prospective, open-label
Disease Myeloproliferative disease(MPD) Myelofibrosis
Age >= 18 years
Status Active
Start of Recruitment 01.04.2012
Leader Reiter, Prof. Dr. med., Andreas
Shortprotocol Shortprotocol
created 10.04.2013 Johannes Kraus
changed 15.05.2013 Sina Hehn
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org